Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
暂无分享,去创建一个
B. Karlan | M. Sliwkowski | D. Agus | M. Press | G. Lieberman | G. Fyfe | M. Gordon | R. Natale | D. Allison | D. Mendelson | S. Kelsey | Charles Taylor
[1] M. Sliwkowski,et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.
[2] M. Sliwkowski,et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.
[3] J. R. Reeves,et al. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.
[4] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Hurwitz,et al. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. , 2003, Seminars in oncology.
[6] M. Sliwkowski,et al. Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models , 2003 .
[7] Carlos L Arteaga,et al. ErbB-targeted therapeutic approaches in human cancer. , 2003, Experimental cell research.
[8] N. Hynes,et al. The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.
[9] M. Sliwkowski. Ready to partner , 2003, Nature Structural Biology.
[10] A. M. Stanley,et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab , 2003, Nature.
[11] Michael Kofler,et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.
[12] A. Harris,et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Keefe,et al. Trastuzumab‐associated cardiotoxicity , 2002, Cancer.
[14] R. Schwall,et al. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. , 2002, Cancer research.
[15] M Paesmans,et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis , 2002, European Respiratory Journal.
[16] J. Kern,et al. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. , 2002, American journal of respiratory cell and molecular biology.
[17] Brian Higgins,et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.
[18] B. Leyland-Jones. Dose Scheduling – Herceptin® , 2001, Oncology.
[19] E K Rowinsky,et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R H Wheeler,et al. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Baselga,et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.
[22] M. Sliwkowski,et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. , 2001, Gastroenterology.
[23] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[24] John Mendelsohn,et al. The EGF receptor family as targets for cancer therapy , 2000, Oncogene.
[25] Yosef Yarden,et al. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.
[26] H. Scher,et al. A potential role for activated HER-2 in prostate cancer. , 2000, Seminars in oncology.
[27] T. K. Yeung,et al. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. , 2000, Biochemical and biophysical research communications.
[28] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[29] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[30] A. Wells,et al. EGF receptor signaling in prostate morphogenesis and tumorigenesis. , 1999, Histology and histopathology.
[31] M. Campiglio,et al. Characteristics of EGFR family‐mediated HRG signals in human ovarian cancer , 1999, Journal of cellular biochemistry.
[32] K L King,et al. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. , 1998, Endocrinology.
[33] H. Friess,et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. , 1998, Human pathology.
[34] M. Sliwkowski,et al. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4 , 1998, FEBS letters.
[35] Y. Yarden,et al. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. , 1998, Biochimica et biophysica acta.
[36] M. Sliwkowski,et al. γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175 , 1997, Oncogene.
[37] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[38] Y. Yarden,et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.
[39] Y. Yarden,et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.
[40] M. Sliwkowski,et al. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. , 1996, Cancer research.
[41] A. Ullrich,et al. Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.
[42] M. Kraus,et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.
[43] M. Sliwkowski,et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.
[44] A. Ullrich,et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.